Evidence Analysis

What is a hazard ratio? A physician's guide to reading longevity trial results

"HR 0.62" appears throughout Geroevidence's intervention index. Here is precisely what the number means, why the confidence interval around it matters as much as the point estimate, and where it's easy to misread.

July 26, 2026  ·  7 min read

RCT vs. observational study: why it matters for longevity medicine claims

Vitamin D, green tea, and taurine each show strong observational associations with longevity. Only some hold up in randomized trials — here is why the study design gap explains most of the confusion.

July 26, 2026  ·  8 min read

Off-label prescribing in longevity medicine: what physicians should know

Nearly every drug tracked on Geroevidence is used off-label for longevity purposes. Here is what that actually means legally and clinically, and what it doesn't.

July 26, 2026  ·  9 min read

How the FDA evaluates anti-aging drug claims (and why "aging" isn't an indication)

No drug is or can currently be FDA-approved for longevity. Here is the specific regulatory reason why, and what the TAME trial's design was built around getting past it.

July 26, 2026  ·  8 min read

Dasatinib monotherapy vs. D+Q: what the senolytics evidence actually covers

Dasatinib is frequently discussed as a standalone senolytic, but every published human senolytic trial has tested it in combination with quercetin. Here is why that distinction matters for the evidence.

July 26, 2026  ·  7 min read

How to evaluate a longevity claim: a physician's guide to reading the evidence

Most longevity claims cite evidence. Most of that evidence is misrepresented, misunderstood, or misapplied. Here is a structured framework for evaluating any longevity intervention claim.

July 19, 2026  ·  12 min read

Surrogate endpoints in longevity medicine: what they mean and what they do not prove

Most longevity interventions are studied using surrogate endpoints — epigenetic clocks, inflammatory markers, mitochondrial gene expression. Here is what those endpoints do and do not establish.

July 19, 2026  ·  11 min read

The NIA Interventions Testing Program: what the most rigorous longevity drug testing found

The ITP has tested dozens of interventions for lifespan extension in mice at three independent sites. Here is what it found — and what the results mean for translating to humans.

July 19, 2026  ·  12 min read

Biological age vs. chronological age: how aging is measured and what the tests tell you

Epigenetic clocks, telomere length, proteomics, metabolomics — multiple methods claim to measure biological age. Here is what each measures, how they compare, and what they cannot tell you.

July 19, 2026  ·  13 min read

Longevity medicine vs. the anti-aging industry: distinguishing science from noise

Both longevity medicine and the anti-aging supplement industry use the same vocabulary. Here is a structured framework for telling them apart — and why the distinction matters clinically.

July 19, 2026  ·  10 min read

Metformin vs. rapamycin: comparing the longevity evidence head-to-head

Both metformin and rapamycin target aging biology through related but distinct pathways. Here is a direct comparison of mechanism, evidence strength, and clinical profile.

July 19, 2026  ·  13 min read

SGLT2 inhibitors vs. GLP-1 agonists: which has stronger longevity evidence?

Both drug classes have strong cardiovascular outcome trial data. Both are prescribed in longevity medicine. Here is how the evidence for each compares across mechanism, outcomes, and patient profile.

July 19, 2026  ·  12 min read

The best-evidenced longevity drugs in 2026, ranked by trial data

Every longevity compound currently tracked on Geroevidence, ranked by evidence strength rather than hype — from Phase III outcome trials down to early-stage signals.

June 24, 2026  ·  12 min read

Why most longevity supplements lack human trial data

A structural explanation of why most longevity supplements have animal data but not human outcome trials — and how to tell the difference when evaluating a claim.

June 24, 2026  ·  8 min read

NAD+ IV therapy vs. NMN and NR supplements: comparing the evidence

NAD+ IV drips have become a popular wellness-clinic offering. Here is how the evidence for IV NAD+ compares to oral NMN and NR precursors.

June 24, 2026  ·  10 min read